Semaglutide loading dose: what happens in the first weeks of Wegovy

You've just started 0.25 mg and nothing seems to be happening

This is the most common concern a prescriber hears in the first month of Wegovy treatment. At 0.25 mg, appetite suppression is usually minimal, and the scales may not move noticeably. That is expected. The first pen's purpose is to introduce semaglutide to your system gently, reducing the chance that nausea or vomiting forces you to stop before the medicine has had a real chance to work.

Semaglutide is a GLP-1 receptor agonist, meaning it activates receptors involved in appetite regulation and gastric emptying. At the starter level, receptor engagement is partial. As the dose increases through the four-week steps (0.5 mg, then 1.0 mg, then 1.7 mg, then the 2.4 mg maintenance level) the effect on appetite and food intake becomes progressively stronger, a pattern explained in detail on the semaglutide dose page. The NHS semaglutide medicines page describes the titration sequence and what to expect at each stage.

A useful way to think about it: the starter weeks are the price of a smoother journey. People who try to skip steps or hold at 0.25 mg for months both miss the point. Stick to the prescriber's schedule, and report anything uncomfortable before deciding to change pace.

Why the dose steps are four weeks apart, and what goes wrong when people rush

Four weeks at each step is not arbitrary. It reflects the time semaglutide needs to reach a steady level in the body and for common side effects (particularly nausea and digestive discomfort) to settle. The gastrointestinal profile of GLP-1 medicines is real: nausea affects a meaningful proportion of people at dose transitions, and it is generally worse the faster you escalate.

A question our prescribers hear most weeks is whether it is safe to push the dose up sooner. The honest answer is that rushing tends to produce more side effects, which leads people to pause or stop treatment altogether, the opposite of what anyone wants. Staying at each level for the recommended period is protective, not passive.

For those thinking about how the starter phase compares across GLP-1 treatments, the full Wegovy dose schedule covers the step-by-step structure in detail, and if you want to understand how the low-end doses behave clinically, the page on semaglutide at low doses addresses that specifically. The decision to stay at a lower dose longer, or to move up, belongs to a prescriber reviewing your response, not to a generic timeline.

The 7.2 mg dose and what it changes about the ceiling

Until early 2026, 2.4 mg was the highest approved maintenance dose for Wegovy in the UK. That changed in April 2026 when the MHRA approved a dedicated single-dose 7.2 mg pen (one weekly injection) for adults with a BMI of 30 or above. The titration principle stays the same: you still begin at 0.25 mg and step upward. The 7.2 mg level is not a starting point for anyone.

Trial data reported around 20.7% average weight loss over 72 weeks at 7.2 mg, which narrows the gap with the results seen in tirzepatide studies. Those are trial averages, not guarantees. The MHRA's announcement of the 7.2 mg pen approval sets out the licensed indication clearly. Patients who are already established on the 2.4 mg injection and want to discuss whether 7.2 mg is appropriate for them should raise it with their prescriber, it is a clinical assessment, not an automatic next step.

The Wegovy overview page covers both dose formats, and the cost context for Wegovy treatment explains what private prescriptions typically include. For anyone comparing the injection with the newer oral option, the full semaglutide doses guide sets both side by side.

Who the Wegovy schedule applies to, and when a prescriber may adjust it

The licensed titration pathway applies to adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability; the prescriber weighs the full clinical picture, including any medicines you already take and conditions that may affect how semaglutide behaves.

Some people tolerate each step very comfortably and ask to progress sooner. Others experience side effects that make a slower approach sensible, staying at a particular step for eight weeks rather than four, for instance. Both adjustments require a prescriber's input. Self-managing the pace based on how you feel, without clinical input, carries real risk of prolonged low-level side effects or of missing a sign that the medicine is not suited to you at all.

If you are considering starting treatment and want to understand how the dose schedule would apply to your situation, checking your eligibility with our prescribers is the right starting point. Every consultation at nume is reviewed the same day by a GPhC-registered prescriber (not automated software) and there are no hidden fees at any stage. You can also read more about how the service works before you begin.